Navigation Links
Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds
Date:12/12/2011

o the combination and continued to improve with additional treatment cycles.

After at least one 28-day cycle, 94 percent had a partial response — at least a 50 percent reduction of the disease. After at least four cycles, all patients had a partial response. After 12 cycles or more, 100 percent of patients had a "very-good partial response," defined as a 90 percent reduction of disease, and four out of five patients showed little or no sign of cancer.

"These response rates are higher than those achieved by the best established regimens for newly diagnosed multiple myeloma," Jakubowiak said.

After a median follow-up of nine and a half months, all patients were alive and only one patient had progression of their cancer. The three-drug combination was overall well-tolerated, with few serious side effects. The side effect that typically limits extended treatment for multiple myeloma — peripheral neuropathy, numbness or tingling of the fingers and toes that can progress to significant pain — was infrequent and mild.

The study included patients who were eligible for a bone marrow transplant using their own stem cells, but offered a deferred transplant approach and only two patients chose that option. Most patients remained on the three-drug treatment and achieved responses similar to or better than those observed after a stem cell transplant. They are still eligible for a stem cell transplant if the disease becomes resistant to the drug combination.

"Newly diagnosed myeloma is most sensitive to treatment," Jakubowiak said. "A great and sustained response in the initial phase of treatment, as is the case in this study, typically projects longer remission, and possibly longer overall survival."

Carfilzomib has recently emerged as an important experimental medicine in the treatment of multiple myeloma. It is a proteasome inhibitor, a drug that interferes with the mechanism that cells use to get rid of unneeded or
'/>"/>

SOURCE University of Chicago Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
4. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
6. New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
7. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
8. FDA Approves Combination Therapy Juvisync
9. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
10. Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
11. New Combination Locking Cap Designed to Protect Children and Teens From Prescription Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Kalorama Information says that ... to be robust; the market is driven by ... global markets, new product innovations and increasing life ... market inhibitors, such as government restraints, limited hospital ... The healthcare market research publisher,s report, Insulin ...
(Date:4/20/2015)... , April 20, 2015  Published results ... trends in the ability of Neuraltus Pharmaceuticals ... of amyotrophic lateral sclerosis (ALS, also known as ... treatment period. While NP001,s slowing of decline in ... was not statistically significant, clinically meaningful slowing of ...
(Date:4/20/2015)... ADDISON, Texas , April 20, 2015 /PRNewswire/ ... have entered a settlement agreement with Inter-Mountain Capital ... with a warrant exercise. Under ... 361,516 shares of Common Stock, issued an unsecured ... Warrant to purchase 194,118 shares of Common Stock ...
Breaking Medicine Technology:Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5ULURU Inc. Announces the Settlement of Outstanding Litigation 2
... ANGELES, Jan. 5, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical, ... Golden Globe Awards introducing new products and giving away freebies ... include its flagship weight loss product, PhenTabz as part of ... celebrities at the upcoming Golden Globe awards in the GBK ...
... /PRNewswire-iReach/ -- FutureNet,s Ambulatory Electronic Health Record ... stamp of approval by earning ONC-ATCB certification. The ... of enabling ambulatory/outpatient providers to qualify for funding ... Tested and certified under the Drummond Group,s Electronic ...
Cached Medicine Technology:Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 2FutureNet Granted Certification for Cloud-based Ambulatory EHR 3
(Date:4/21/2015)... On Saturday, May 2nd, 2015, board ... his team from Georgia Eye Physicians and Surgeons ... Now, being held in Piedmont Park by the Lupus ... be the largest LFA-sponsored walk in the nation, hosting ... funds and awareness for lupus, an unpredictable and potentially ...
(Date:4/21/2015)... “The warm summer season is fast approaching,” says Marta ... younger than her age? In the ongoing battle against ... Signs of premature aging are deep wrinkles and unsightly ... spent in the sun without adequate protection.” , Outward appearances ... dangers of UV rays can go deep below the surface. ...
(Date:4/20/2015)... (PRWEB) April 21, 2015 Using Quality ... CMOs Speed Production and Improve Compliance , **FDAnews Webinar**, ... EDT, http://www.fdanews.com/qualitybydesign , The life sciences industries ... them to do more with less. Mergers, acquisitions, ... CMOs to finds ways to speed up production while ...
(Date:4/20/2015)... City, NY (PRWEB) April 21, 2015 ... as a 2015 Professional Woman of the Year. Ms. ... in healthcare. As the largest, most-recognized networking organization of ... and profession, the National Association of Professional Women is ... and over 200 local chapters. , “We are like ...
(Date:4/20/2015)... 20, 2015 The NFL draft season is ... players to add to their rosters, both for their skills ... this episode of SCI TV , Vinnie Iyer ... of Greg Hardy given increased attention on off-field conduct in ... after the Ray Rice scandal brought media scrutiny, once again, ...
Breaking Medicine News(10 mins):Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:National Association of Professional Women Announces Suzanne Webb, Chief Executive Officer at Exclusive Surgeries Network, LLC, a 2015 Professional Woman of the Year 2Health News:Character Concerns in the NFL with Vinnie Iyer on SCI TV 2
... surveillance is an acceptable alternative to surgical excision in ... without cell abnormalities, a new study shows. , The ... Pacific Medical Center in San Francisco, included 119 papillomas ... follow-up of a minimum of two years without surgical ...
... 2 (HealthDay News) -- Aspirin is just as effective as ... failure patients with a normal heart rhythm, a landmark ... researchers from Columbia University in New York City said their ... because it is much cheaper. The 10-year study was ...
... the University of California, Davis, are among 12 scientists ... Hartwell Foundation this year. The awards provide $100,000 of ... well as videoconferencing equipment for periodic communications with the ... funding a UC Davis Hartwell Foundation postdoctoral researcher with ...
... West Orange, NJ. May 2, 2012. Kessler Foundation will be ... on Cognition in Multiple Sclerosis to be held at the ... 2012. John DeLuca, PhD, the Foundation,s VP of Research and ... Strober, PhD, and James Sumowski, PhD. Kessler Foundation ...
... - The University of Texas MD Anderson Cancer Center President ... of Sciences (NAS) - one of the most prestigious accolades ... and engineering. DePinho is the first member of the ... The NAS is a private, nonprofit society of distinguished ...
... NY(May 1, 2012) Large majorities of older Americans ... according to a new national survey, "How Does It ... by the John A. Hartford Foundation, a champion for ... Institute for Geriatric Nursing at New York University,s College ...
Cached Medicine News:Health News:Surgical excision unnecessary in some patients with benign papillomas 2Health News:Aspirin as Effective as Warfarin for Heart Failure: Study 2Health News:Biomedical researchers receive Hartwell Foundation awards 2Health News:Biomedical researchers receive Hartwell Foundation awards 3Health News:UT MD Anderson President Ronald DePinho elected to National Academy of Sciences 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: